Cargando…

Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates

Mammalian paraoxonase-1 hydrolyses a very broad spectrum of esters such as certain drugs and xenobiotics. The aim of this study was to determine whether carbamates influence the activity of recombinant PON1 (rePON1). Carbamates were selected having a variety of applications: bambuterol and physostig...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosak, Anita, Bavec, Aljoša, Konte, Tilen, Šinko, Goran, Kovarik, Zrinka, Goličnik, Marko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983073/
https://www.ncbi.nlm.nih.gov/pubmed/31947900
http://dx.doi.org/10.3390/molecules25010211
_version_ 1783491435875532800
author Bosak, Anita
Bavec, Aljoša
Konte, Tilen
Šinko, Goran
Kovarik, Zrinka
Goličnik, Marko
author_facet Bosak, Anita
Bavec, Aljoša
Konte, Tilen
Šinko, Goran
Kovarik, Zrinka
Goličnik, Marko
author_sort Bosak, Anita
collection PubMed
description Mammalian paraoxonase-1 hydrolyses a very broad spectrum of esters such as certain drugs and xenobiotics. The aim of this study was to determine whether carbamates influence the activity of recombinant PON1 (rePON1). Carbamates were selected having a variety of applications: bambuterol and physostigmine are drugs, carbofuran is used as a pesticide, while Ro 02-0683 is diagnostic reagent. All the selected carbamates reduced the arylesterase activity of rePON1 towards the substrate S-phenyl thioacetate (PTA). Inhibition dissociation constants (K(i)), evaluated by both discontinuous and continuous inhibition measurements (progress curves), were similar and in the mM range. The rePON1 displayed almost the same values of K(i) constants for Ro 02-0683 and physostigmine while, for carbofuran and bambuterol, the values were approximately ten times lower and two times higher, respectively. The affinity of rePON1 towards the tested carbamates was about 3–40 times lower than that of PTA. Molecular modelling of rePON1-carbamate complexes suggested non-covalent interactions with residues of the rePON1 active site that could lead to competitive inhibition of its arylesterase activity. In conclusion, carbamates can reduce the level of PON1 activity, which should be kept in mind, especially in medical conditions characterized by reduced PON1 levels.
format Online
Article
Text
id pubmed-6983073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69830732020-02-06 Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates Bosak, Anita Bavec, Aljoša Konte, Tilen Šinko, Goran Kovarik, Zrinka Goličnik, Marko Molecules Article Mammalian paraoxonase-1 hydrolyses a very broad spectrum of esters such as certain drugs and xenobiotics. The aim of this study was to determine whether carbamates influence the activity of recombinant PON1 (rePON1). Carbamates were selected having a variety of applications: bambuterol and physostigmine are drugs, carbofuran is used as a pesticide, while Ro 02-0683 is diagnostic reagent. All the selected carbamates reduced the arylesterase activity of rePON1 towards the substrate S-phenyl thioacetate (PTA). Inhibition dissociation constants (K(i)), evaluated by both discontinuous and continuous inhibition measurements (progress curves), were similar and in the mM range. The rePON1 displayed almost the same values of K(i) constants for Ro 02-0683 and physostigmine while, for carbofuran and bambuterol, the values were approximately ten times lower and two times higher, respectively. The affinity of rePON1 towards the tested carbamates was about 3–40 times lower than that of PTA. Molecular modelling of rePON1-carbamate complexes suggested non-covalent interactions with residues of the rePON1 active site that could lead to competitive inhibition of its arylesterase activity. In conclusion, carbamates can reduce the level of PON1 activity, which should be kept in mind, especially in medical conditions characterized by reduced PON1 levels. MDPI 2020-01-04 /pmc/articles/PMC6983073/ /pubmed/31947900 http://dx.doi.org/10.3390/molecules25010211 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bosak, Anita
Bavec, Aljoša
Konte, Tilen
Šinko, Goran
Kovarik, Zrinka
Goličnik, Marko
Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
title Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
title_full Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
title_fullStr Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
title_full_unstemmed Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
title_short Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates
title_sort interactions of paraoxonase-1 with pharmacologically relevant carbamates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983073/
https://www.ncbi.nlm.nih.gov/pubmed/31947900
http://dx.doi.org/10.3390/molecules25010211
work_keys_str_mv AT bosakanita interactionsofparaoxonase1withpharmacologicallyrelevantcarbamates
AT bavecaljosa interactionsofparaoxonase1withpharmacologicallyrelevantcarbamates
AT kontetilen interactionsofparaoxonase1withpharmacologicallyrelevantcarbamates
AT sinkogoran interactionsofparaoxonase1withpharmacologicallyrelevantcarbamates
AT kovarikzrinka interactionsofparaoxonase1withpharmacologicallyrelevantcarbamates
AT golicnikmarko interactionsofparaoxonase1withpharmacologicallyrelevantcarbamates